

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6909541

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	LES LABORATOIRES SERVIER	08/11/2021
RECEIVING PARTY DATA		
Name:	GALAPAGOS NV	
Street Address:	GENERAAL DE WITTELAAN L11/A3	
City:	MECHELEN	
State/Country:	BELGIUM	
Postal Code:	2800	
PROPERTY NUMBERS Total: 4		
Property Type	Number	
Application Number:	15538393	
Application Number:	15896779	
Application Number:	16653668	
Application Number:	17141902	
CORRESPONDENCE DATA		
Fax Number:	(202)857-6395	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	2028576000	
Email:	gregory.forbes@arentfox.com,patentdocket@arentfox.com	
Correspondent Name:	ARENT FOX LLP	
Address Line 1:	1717 K ST NW	
Address Line 4:	WASHINGTON, D.C. 20006	
ATTORNEY DOCKET NUMBER:	038581.00056	
NAME OF SUBMITTER:	GREGORY M. FORBES	
SIGNATURE:	/Gregory M. Forbes/	
DATE SIGNED:	09/10/2021	
Total Attachments: 6		
source=2021.08.25_Assignment Servier to Galapagos NV#page1.tif		
source=2021.08.25_Assignment Servier to Galapagos NV#page2.tif		
source=2021.08.25_Assignment Servier to Galapagos NV#page3.tif		

source=2021.08.25_Assignment Servier to Galapagos NV#page4.tif

source=2021.08.25_Assignment Servier to Galapagos NV#page5.tif

source=2021.08.25_Assignment Servier to Galapagos NV#page6.tif

ASSIGNMENT AGREEMENT

WHEREAS Galapagos NV ("**Assignee**"), a company incorporated in Belgium whose registered address is Generaal de Wittelaan L11/A3, 2800 Mechelen, Belgium and Les Laboratoires Servier ("**Assignor**"), a company incorporated in France whose registered address is 35 rue de Verdun, 92284 Suresnes, France, jointly own certain inventions (hereinafter called "**the Inventions**") for which patent applications listed in Annex A have been applied for or granted (hereinafter called "**the Patent applications**").

WHEREAS Assignee is desirous of acquiring from Assignor the whole right, title and interest in and to the **Inventions and the Patent applications** in and throughout all territories of the world;

NOW, THEREFORE, to all whom it may concern be it known that **WE Assignor** having received good and valuable consideration of One (1) Euro the sufficiency of which is acknowledged hereby assign and transfer to **Assignee** our whole right, title and interest in and to the **Inventions and the Patent applications** and to any priority rights for all territories of the world in respect of the **Inventions and the Patent applications** and in and to any patent application that may be filed in any and all territories of the world relating to the Inventions, and in and to any divisional application, continuation or continuation in part application thereof, and in and to any extension, or re-issue thereof, or Supplementary Protection Certificate based thereon, and including the right to sue for past infringement;

AND Assignee hereby accepts the assignment and transfer of the whole right, title and interest in and to the **Inventions and the Patent applications**.

AND Assignor agrees to provide information and make execute and deliver any and all other instruments in writing, and any and all further acts, applications, papers, affidavits, assignments and other documents which may be possible and are necessary or desirable to more effectually secure to and vest in **Assignee**, its successors and assigns, our whole right, title and interest in and to the **Inventions and the Patent applications**.

This agreement shall be governed by and construed according to Belgian law and the parties agree to submit any dispute arising out of or under this agreement to the exclusive jurisdiction of the Belgian Courts.

IN WITNESS whereof and with effect from *11 August, 2021* **Assignor and Assignee** through its authorised officials have hereunto set their respective hands.

SIGNED by

LES LABORATOIRES SERVIER




Name Sylvie JAVELIN

Capacity PATENT DIRECTOR

SIGNED by

GALAPAGOS NV



Name Piet Wigerinck

Capacity Chief Scientific Officer

ANNEX A – Patent Applications

GAL-223: 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis			
<i>Case reference</i>	<i>Country</i>	<i>Application Number</i>	<i>Grant Number</i>
GAL-223-AE-PCT	United Arab Emirates	P6000772/2017	
GAL-223-AL-EPT	Albania	EP15813831.3	3237406
GAL-223-AM-EAT	Armenia	201791451	030637
GAL-223-AP-AFT	ARIPO	AP/P/2017/010136	AP 5135
GAL-223-AR-NP	Argentina	P150104189	
GAL-223-AT-EPT	Austria	EP15813831.3	3237406
GAL-223-AU-PCT	Australia	2015371400	2015371400
GAL-223-AZ-EAT	Azerbaijan	201791451	030637
GAL-223-BA-EPT	Bosnia-Herzegovina	EP15813831.3	E3095
GAL-223-BD-NP	Bangladesh	305/2015	
GAL-223-BE-EPT	Belgium	EP15813831.3	3237406
GAL-223-BG-EPT	Bulgaria	EP15813831.3	3237406
GAL-223-BH-PCT	Bahrain	20170119	
GAL-223-BR-PCT	Brazil	BR112017013258-3	
GAL-223-BY-EAT	Belarus	201791451	030637
GAL-223-CA-PCT	Canada	2971110	
GAL-223-CH-EPT	Switzerland	EP15813831.3	3237406
GAL-223-CL-PCT	Chile	1650-2017	62.065
GAL-223-CN-PCT	China	201580070274.0	ZL201580070274.0
GAL-223-CO-PCT	Colombia	NC2017/0006174	NC2017/0006174
GAL-223-CR-PCT	Costa Rica	2017-0248	
GAL-223-CY-EPT	Cyprus (Republic)	EP15813831.3	CY1121692
GAL-223-CZ-EPT	Czechia	EP15813831.3	3237406
GAL-223-DE-EPT	Germany	EP15813831.3	3237406
GAL-223-DK-EPT	Denmark	EP15813831.3	3237406
GAL-223-DO-PCT	Dominican Republic	P2017-0139	
GAL-223-DZ-PCT	Algeria	170380	9934
GAL-223-EA-EAT	Eurasian Procedure	201791451	030637
GAL-223-EE-EPT	Estonia	EP15813831.3	3237406
GAL-223-EG-PCT	Egypt	PCT1026/2017	

GAL-223: 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis			
Case reference	Country	Application Number	Grant Number
GAL-223-EP-EPT	European Procedure (Patents)	EP15813831.3	3237406
GAL-223-ES-EPT	Spain	EP15813831.3	3237406
GAL-223-FI-EPT	Finland	EP15813831.3	3237406
GAL-223-FR-EPT	France	EP15813831.3	3237406
GAL-223-GB-EPT	United Kingdom	EP15813831.3	3237406
GAL-223-GC-NP	Gulf Cooperation Council	2015/30633	
GAL-223-GE-PCT	Georgia	AP201514546	P 2019 7043
GAL-223-GR-EPT	Greece	EP15813831.3	3237406
GAL-223-GT-PCT	Guatemala	A-2017000107	
GAL-223-HK-FPR[2]	Hong Kong	18105455.7	HK1245793
GAL-223-HR-EPT	Croatia	EP15813831.3	3237406
GAL-223-HU-EPT	Hungary	EP15813831.3	3237406
GAL-223-ID-PCT	Indonesia	PID201704696	IDP000070544
GAL-223-IE-EPT	Ireland	EP15813831.3	3237406
GAL-223-IL-PCT	Israel	252981	252981
GAL-223-IN-PCT	India	201727020540	
GAL-223-IS-EPT	Iceland	EP15813831.3	3237406
GAL-223-IT-EPT	Italy	EP15813831.3	3237406
GAL-223-JO-NP	Jordan	284/2015	3501
GAL-223-JP-PCT	Japan	2017-551003	6636539
GAL-223-KG-EAT	Kirghizstan	201791451	030637
GAL-223-KR-PCT	South Korea / Republic of Korea	10-2017-7020379	
GAL-223-KS-NP	KOSOVO	KS/P/2015/000054	1055
GAL-223-KZ-EAT	Kazakhstan	201791451	030637
GAL-223-LB-NP	Lebanon	10807	10807
GAL-223-LK-PCT	Sri Lanka	19355	
GAL-223-LT-EPT	Lithuania	EP15813831.3	3237406
GAL-223-LU-EPT	Luxembourg	EP15813831.3	3237406
GAL-223-LV-EPT	Latvia	EP15813831.3	3237406
GAL-223-MA-EPT	Morocco	EP15813831.3	41238

GAL-223: 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis

<i>Case reference</i>	<i>Country</i>	<i>Application Number</i>	<i>Grant Number</i>
GAL-223-MC-EPT	Monaco	EP15813831.3	3237406
GAL-223-MD-EPT	Moldova (Rep)	EP15813831.3	3237406
GAL-223-ME-EPT	Montenegro	EP15813831.3	00374
GAL-223-MK-EPT	North Macedonia	EP15813831.3	909664
GAL-223-MT-EPT	Malta	EP15813831.3	3237406
GAL-223-MX-PCT	Mexico	MX/a/2017/008048	371604
GAL-223-MY-PCT	Malaysia	PI2017702301	
GAL-223-NG-PCT	Nigeria	F/P/2017/330	F/P/2017/330
GAL-223-NI-PCT	Nicaragua	2017/0081	2727RPI
GAL-223-NL-EPT	Netherlands	EP15813831.3	3237406
GAL-223-NO-EPT	Norway	EP15813831.3	3237406
GAL-223-NZ-PCT	New Zealand	732909	732909
GAL-223-OA-PCT	OAPI	1201700232	
GAL-223-PA-PCT	Panama	91715-01	
GAL-223-PE-PCT	Peru	001122-2017/DIN	
GAL-223-PH-PCT	Philippines	1-2017-501160	
GAL-223-PK-NP	Pakistan	825/2015	143195
GAL-223-PL-EPT	Poland	EP15813831.3	3237406
GAL-223-PT-EPT	Portugal	EP15813831.3	3237406
GAL-223-PY-NP	Paraguay	78473/2015	
GAL-223-RO-EPT	Romania	3237406	3237406
GAL-223-RS-EPT	Serbia (ex-Serbia & Montenegro)	EP15813831.3	58617
GAL-223-RU-EAT	Russian Federation	201791451	030637
GAL-223-RU-PCT	Russian Federation	2017126187	2693459
GAL-223-SA-PCT	Saudi Arabia	517381743	SA 7504
GAL-223-SE-EPT	Sweden	EP15813831.3	3237406
GAL-223-SG-PCT	Singapore	11201705030S	11201705030S
GAL-223-SI-EPT	Slovenia	EP15813831.3	3237406
GAL-223-SK-EPT	Slovakia	EP15813831.3	3237406
GAL-223-SV-PCT	El Salvador	2017005452	
GAL-223-TH-PCT	Thailand	1701003474	
GAL-223-TJ-EAT	Tajikistan	201791451	030637

GAL-223: 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS inhibitors for the treatment of osteoarthritis			
Case reference	Country	Application Number	Grant Number
GAL-223-TM-EAT	Turkmenistan	201791451	030637
GAL-223-TN-PCT	Tunisia	TN2017/0213	
GAL-223-TR-EPT	Turkey	EP15813831.3	TR201904158
GAL-223-TW-NP	Taiwan	104141953	I687414
GAL-223-UA-PCT	Ukraine	a 2017 07702	122065
GAL-223-US-CNT	United States Of America	15/896779	10487060
GAL-223-US-CNT[2]	United States Of America	US16/653,668	US10,941,117
GAL-223-US-CNT[3]	United States Of America	US17/141,902	
GAL-223-US-PCT	United States Of America	15/538,393	9926281
GAL-223-UY-NP	Uruguay	36.470	
GAL-223-UZ-PCT	Uzbekistan	IAP 20170287	
GAL-223-VN-PCT	Vietnam	1-2017-02476	
GAL-223-ZA-PCT	South Africa	2017/03905	

GAL-327: SOLID FORMS OF (5S)-CYCLOPROPYL-5-[3-[(3S)-4-(3,5-DIFLUOROPHENYL)-3-METHYL-PIPERAZIN-1-YL]-3-OXO-PROPYL]IMIDAZOLIDINE-2,4-DIONE			
Case reference	Country	Filing Number	Grant Number
GAL-327-EP-EPA	European Procedure (Patents)	EP20306578.4	
GAL-327-EP-EPA(2)	European Procedure (Patents)	EP21170505.8	